In this section
Gastro-oesphageal reflux, irritability or unsettled behaviours are experienced by a number of healthy, thriving infants. As the infant gets older, these issues tend to resolve spontaneously without the need for medical intervention. However, caring for an infant with gastro-oesophageal reflux, irritability or unsettled
behaviours can be very challenging for parents and require support.
In an effort to help resolves these issues, infants are sometimes prescribed acid suppression therapies (AST). AST medications include proton pump inhibitors (e.g. omeprazole) and/or H2 receptor antagonists (e.g. ranitidine). What we know from the latest
research is that these medications have been shown to have no benefit for infants with gastro-oesophageal reflux, irritability or unsettled behaviours - in fact, AST medications can cause harm in infants.
Between May 2018 to April 2020, HSRU led a project aimed at reducing unnecessary prescribing of ASTs in infants in partnership with Safer Care Victoria. As part of the REMEDI project, a suite of resources were developed for clinicians and parents to:
The suite of resources were co-developed with a consumer representative and clinicians from the three pilot sites who participated in the REMEDI project. Positive feedback was received from parents and clinicians about the resources. All of the resources developed are in line with the current RCH Clinical Practice
Guidelines (CPG) for
Gastro-oesophageal reflux disease in infants and
Unsettled or crying babies. We are excited to share the range of parent and clinician resources.